ABIONYX Pharma SA (609.F)
- Previous Close
0.9710 - Open
0.9570 - Bid 0.9600 x 50000
- Ask 1.0980 x 50000
- Day's Range
0.9570 - 0.9570 - 52 Week Range
0.8540 - 1.9060 - Volume
250 - Avg. Volume
25 - Market Cap (intraday)
33.456M - Beta (5Y Monthly) -0.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.
abionyx.comRecent News: 609.F
Performance Overview: 609.F
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 609.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 609.F
Valuation Measures
Market Cap
33.43M
Enterprise Value
35.76M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.80
Price/Book (mrq)
6.51
Enterprise Value/Revenue
7.77
Enterprise Value/EBITDA
-11.18
Financial Highlights
Profitability and Income Statement
Profit Margin
-76.09%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
4.6M
Net Income Avi to Common (ttm)
-3.5M
Diluted EPS (ttm)
-0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Company Insights: 609.F
609.F does not have Company Insights